Canaccord analyst Edward Nash initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $89 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics Highlights Pipeline Progress and Financials
- Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
- Apogee Therapeutics, Inc. (APGE) Q3 Earnings Cheat Sheet
- Apogee Therapeutics price target raised to $100 from $81 at BTIG
- Apogee Therapeutics Unveils Promising Phase 1 Trial Results